Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue

globenewswire.com
GSK GSK is mentioned as investing in innovative treatments for the growing UTI treatment market, indicating potential involvement and interest in this sector. PFE Pfizer is mentioned as investing in innovative treatments for the growing UTI treatment market, indicating potential involvement and interest in this sector. MRK Merck is mentioned as investing in innovative treatments for the growing UTI treatment market, indicating potential involvement and interest in this sector.

Dublin, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The "Competitor Analysis of Urinary Tract Infection Treatment Market, Forecast by Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue" report has been added to ResearchAndMarkets.com's offering.

The Urinary Tract Infection Treatment industry is expected to expand lucratively to an estimated value of US$ 11.64 Billion by 2033, from US$ 9.13 Billion in 2024. This expansion reflects a compound annual growth rate (CAGR) of 2.73% between 2025 and 2033.

The Urinary Tract Infection (UTI) Treatment Market is experiencing steady growth due to rising prevalence of UTIs, increased awareness of early diagnosis, and advancements in antibiotic and non-antibiotic therapies. Factors such as aging populations, higher rates of catheter-associated infections, and growing female patient demographics are fueling demand. Innovative treatments, including vaccines, probiotics, and phage therapy, are gaining traction as antibiotic resistance becomes a concern.

North America dominates the market, while Asia-Pacific shows strong growth potential due to improved healthcare access and awareness. The World Health Organization (WHO) claims that antibiotic resistance poses a serious threat to global health and makes it more difficult to treat common illnesses, such as urinary tract infections.

Due to rising healthcare costs, companies like GSK, Pfizer, and Merck are investing in innovative treatments and diagnostic equipment to improve treatment efficacy in the growing worldwide UTI treatment market. According to the CDC's 2023 study, Escherichia coli is the most frequent cause of UTIs, accounting for about 2.8 million drug-resistant infections in the United States each year. Because older persons are more vulnerable, the growing elderly population - which the UN estimates will reach 1.5 billion by 2050 - also contributes to an increase in UTI infections.

Key Attributes:

Company Analysis

Overview

Key Persons

Recent Development & Strategies

Sustainability Analysis

Product Analysis

Strategic Assessment: SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/9m3wcf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment